BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

27 related articles for article (PubMed ID: 24386807)

  • 1. Activation of the
    Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
    Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIM domain only-2 (LMO2) induces T-cell leukemia by two distinct pathways.
    Smith S; Tripathi R; Goodings C; Cleveland S; Mathias E; Hardaway JA; Elliott N; Yi Y; Chen X; Downing J; Mullighan C; Swing DA; Tessarollo L; Li L; Love P; Jenkins NA; Copeland NG; Thompson MA; Du Y; Davé UP
    PLoS One; 2014; 9(1):e85883. PubMed ID: 24465765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a minority population of LMO2
    Sikandar SS; Gulati GS; Antony J; Fetter I; Kuo AH; Ho WHD; Haro-Acosta V; Das S; Steen CB; Pereira TA; Qian D; Beachy PA; Dirbas FM; Red-Horse K; Rabbitts TH; Thiery JP; Newman AM; Clarke MF
    Sci Adv; 2022 Nov; 8(45):eabm3548. PubMed ID: 36351009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive analysis of LMO2 pathogenic regulatory profile during T-lineage development and leukemic transformation.
    Wang W; Meng Y; Chen Y; Yu Y; Wang H; Yang S; Sun W
    Oncogene; 2022 Aug; 41(34):4079-4090. PubMed ID: 35851847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cell-based screening method using an intracellular antibody for discovering small molecules targeting the translocation protein LMO2.
    Bery N; Bataille CJR; Russell A; Hayes A; Raynaud F; Milhas S; Anand S; Tulmin H; Miller A; Rabbitts TH
    Sci Adv; 2021 Apr; 7(15):. PubMed ID: 33837087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Competitive SPR using an intracellular anti-LMO2 antibody identifies novel LMO2-interacting compounds.
    Canning P; Bataille C; Bery N; Milhas S; Hayes A; Raynaud F; Miller A; Rabbitts T
    J Immunol Methods; 2021 Jul; 494():113051. PubMed ID: 33794223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LMO2 is essential to maintain the ability of progenitors to differentiate into T-cell lineage in mice.
    Hirano KI; Hosokawa H; Koizumi M; Endo Y; Yahata T; Ando K; Hozumi K
    Elife; 2021 Aug; 10():. PubMed ID: 34382935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LMO2 induces T-cell leukemia with epigenetic deregulation of CD4.
    Cleveland SM; Goodings C; Tripathi RM; Elliott N; Thompson MA; Guo Y; Shyr Y; Davé UP
    Exp Hematol; 2014 Jul; 42(7):581-93.e5. PubMed ID: 24792354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Red Sorghum-Derived Deoxyanthocyanidins and Their O-β-D-Glucosides on E-Cadherin Promoter Activity in PC-3 Prostate Cancer Cells.
    Mora N; Rosa M; Touaibia M; Martin LJ
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LMO2 at 25 years: a paradigm of chromosomal translocation proteins.
    Chambers J; Rabbitts TH
    Open Biol; 2015 Jun; 5(6):150062. PubMed ID: 26108219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taking a STAP at Core Promoter-Transcriptional Cofactor Specificity.
    Siegenfeld AP; Lee C; Liau BB
    Biochemistry; 2019 Jul; 58(29):3133-3135. PubMed ID: 31298845
    [No Abstract]   [Full Text] [Related]  

  • 12. [Regulation of E-cadherin promoter activity by LMO2 impact on the progression and metastasis of prostate cancer].
    Peng X; Ye Z; Gao Y
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2013 Sep; 29(5):385-9. PubMed ID: 24386807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of LMO2 in Prostate Carcinoma and Adjacent Prostatic Parenchyma.
    Krušlin B; Vučić M; Mašić S; Kruljac I; Lež C; Ružić B; Spajić B; Ulamec M
    Acta Clin Croat; 2018 Oct; 57(Suppl 1):56-60. PubMed ID: 30457249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LMO2 promotes tumor cell invasion and metastasis in basal-type breast cancer by altering actin cytoskeleton remodeling.
    Liu Y; Wang Z; Huang D; Wu C; Li H; Zhang X; Meng B; Li Z; Zhu T; Yang S; Sun W
    Oncotarget; 2017 Feb; 8(6):9513-9524. PubMed ID: 27880729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LMO2 attenuates tumor growth by targeting the Wnt signaling pathway in breast and colorectal cancer.
    Liu Y; Huang D; Wang Z; Wu C; Zhang Z; Wang D; Li Z; Zhu T; Yang S; Sun W
    Sci Rep; 2016 Oct; 6():36050. PubMed ID: 27779255
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.